Dr. Reddy's Laboratories Ltd (RDY): Price and Financial Metrics


Dr. Reddy's Laboratories Ltd (RDY): $74.20

0.14 (+0.19%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

RDY POWR Grades


  • RDY scores best on the Stability dimension, with a Stability rank ahead of 96.43% of US stocks.
  • The strongest trend for RDY is in Quality, which has been heading down over the past 31 weeks.
  • RDY ranks lowest in Momentum; there it ranks in the 11th percentile.

RDY Stock Summary

  • The price/operating cash flow metric for Dr Reddys Laboratories Ltd is higher than just 1.95% of stocks in our set with a positive cash flow.
  • The volatility of Dr Reddys Laboratories Ltd's share price is greater than that of only 5.41% US stocks with at least 200 days of trading history.
  • Dr Reddys Laboratories Ltd's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is 197.42%, greater than the shareholder yield of 98.53% of stocks in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Dr Reddys Laboratories Ltd are VIV, EME, TPL, TFII, and HSIC.
  • Visit RDY's SEC page to see the company's official filings. To visit the company's web site, go to www.drreddys.com.

RDY Stock Price Chart Interactive Chart >

Price chart for RDY

RDY Price/Volume Stats

Current price $74.20 52-week high $74.39
Prev. close $74.06 52-week low $51.12
Day low $74.01 Volume 43,900
Day high $74.39 Avg. volume 179,229
50-day MA $69.48 Dividend yield 0.36%
200-day MA $66.46 Market Cap 12.34B

Dr. Reddy's Laboratories Ltd (RDY) Company Bio


Dr. Reddy's Laboratories operates as an integrated pharmaceutical company worldwide. It operates in three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. The company was founded in 1984 and is based in Hyderabad, India.

RDY Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$74.20$1058.48 1363%

The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for Dr Reddys Laboratories Ltd. To summarize, we found that Dr Reddys Laboratories Ltd ranked in the 91th percentile in terms of potential gain offered. Specifically, our DCF analysis implies the stock is trading below its fair value by an estimated 1370.5%. In terms of the factors that were most noteworthy in this DCF analysis for RDY, they are:

  • The compound growth rate in the free cash flow of Dr Reddys Laboratories Ltd over the past 3.98 years is -0.03%; that's better than only 16.6% of cash flow producing equities in the Healthcare sector, where it is classified.
  • RDY's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 3%; for context, that number is higher than 52.71% of tickers in our DCF set.
  • Dr Reddys Laboratories Ltd's effective tax rate, as measured by taxes paid relative to net income, is at 0 -- greater than only 0% of US stocks with positive free cash flow.


Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price
0%1335%
1%1349%
2%1363%
3%1378%
4%1392%
5%1406%

SEM, MODV, CORT, CYH, and AHCO can be thought of as valuation peers to RDY, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.


RDY Latest News Stream


Event/Time News Detail
Loading, please wait...

RDY Latest Social Stream


Loading social stream, please wait...

View Full RDY Social Stream

Latest RDY News From Around the Web

Below are the latest news stories about Dr Reddys Laboratories Ltd that investors may wish to consider to help them evaluate RDY as an investment opportunity.

7 Best Vaccine Stocks for Their Pipeline Potential

These Covid-19 vaccine stocks may be late in the race, but they certainly have growth potential as we head into the summer.

Faisal Humayun on InvestorPlace | June 3, 2021

Global Response Aid Reports Midyear Sales Results for COVID Drug

Healthcare solutions provider Global Response Aid (GRA) today reported seven-month global sales figures for its anti-viral tablet Avigan®/Reeqonus™, a drug being used in several countries to treat patients with mild to moderate cases of COVID-19.

Yahoo | June 3, 2021

Dr. Reddy's in talks to bring single-dose Sputnik Light vaccine in India

Dr. Reddy's Laboratories (RDY) has started talks with the government to bring Russia's Sputnik Light COVID-19 vaccine into the country, a company spokesperson has told Reuters.A positive outcome could make Sputnik Light the first single-dose COVID-19 shot to be launched in India.The Sputnik Light vaccine is the first component (recombinant human...

Seeking Alpha | May 31, 2021

Dr. Reddy's in talks to bring single-dose Sputnik Light vaccine

Dr. Reddy's Laboratories (RDY) has started talks with the government to bring Russia's Sputnik Light COVID-19 vaccine into the country, a company spokesperson has told Reuters.A positive outcome could make Sputnik Light the first single-dose COVID-19 shot to be launched in India.The Sputnik Light vaccine is the first component (recombinant human...

Seeking Alpha | May 31, 2021

Dr Reddy's developing new Covid treatment options: MD

"We are motivated to serve patients in every possible way and with utmost urgency. This is reflected in the multiple collaborations we have entered to develop and commercialise a wide range of preventive and curative options for COVID treatment," Dr Reddy's Laboratories Co-Chairman & Managing Director G V Prasad said in an analyst call.

Economic Times India | May 23, 2021

Read More 'RDY' Stories Here

RDY Price Returns

1-mo 3.06%
3-mo 24.20%
6-mo 7.90%
1-year 38.52%
3-year 115.95%
5-year 67.99%
YTD 4.08%
2020 76.61%
2019 8.38%
2018 1.18%
2017 -16.47%
2016 -1.67%

RDY Dividends

Ex-Dividend Date Type Payout Amount Change
Loading, please wait...
View Full RDY Dividend History

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.8328 seconds.